Literature DB >> 25313732

Comparing outcomes in poorly-differentiated versus anaplastic thyroid cancers treated with radiation: a surveillance, epidemiology, and end results analysis.

Shruthi Arora, Paul Christos, Anthony Pham, Prashant Desai, A Gabriella Wernicke, Dattatreyudu Nori, K S C Chao, Bhupesh Parashar1.   

Abstract

PURPOSE: Poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC) are considered the most aggressive cancers of the head and neck. The aim of the study was to evaluate and compare survival outcomes in PDTC and ATC in a large population-based cohort.
MATERIALS AND METHODS: Patients with PDTC and ATC diagnosed from 1973 to 2008 were obtained from Surveillance, Epidemiology, and End RESULTS database. Kaplan-Meier survival analysis and log-rank analyses were performed to evaluate (1) The effect of histology on cause-specific survival (CSS) and (2) the influence of factors such as treatment, treatment sequence, race, sex, and age on CSS. Multivariate analysis was performed to assess the independent effect of these factors on CSS.
RESULTS: A total of 1352 patients with PDTC and ATC were identified. PDTC constituted 52.4% of patients versus 47.6% for ATC. Median CSS was similar in the two histology groups (P = 0.14). Both PDTC and ATC patients receiving radioisotopes showed a significantly better CSS compared to external beam radiation (P < 0.0001). PDTC and ATC Patients receiving radiation prior to surgery demonstrated a significantly lower CSS compared to patients receiving radiation postoperatively (P < 0.0001). Female gender and black/nonwhite race tended to improve CSS in PDTC and ATC patients (P = 0.29 and P = 0.03, for gender and race, respectively). However, multivariate analysis revealed only type of radiation treatment and age to be independently associated with CSS.
CONCLUSION: This is the first large population-based study evaluating PDTC and ATC outcomes in patients who received radiation treatment. Radioisotope use and timing of radiotherapy (postoperative vs. preoperative) were associated with improved CSS in both histologies.

Entities:  

Mesh:

Year:  2014        PMID: 25313732     DOI: 10.4103/0973-1482.138207

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  5 in total

1.  [Not Available].

Authors:  C Lenschow; K Lindner; A K Müller; P Barth; N Senninger; M Colombo-Benkmann
Journal:  Chirurg       Date:  2016-03       Impact factor: 0.955

2.  The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis.

Authors:  Bo Lin; Haiqing Ma; Maoguang Ma; Zhicheng Zhang; Zicheng Sun; I-Yun Hsieh; Okose Okenwa; Haoyan Guan; Jie Li; Weiming Lv
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

3.  Synergy of GSK-J4 With Doxorubicin in KRAS-Mutant Anaplastic Thyroid Cancer.

Authors:  Bo Lin; Bing Lu; I-Yun Hsieh; Zhen Liang; Zicheng Sun; Yang Yi; Weiming Lv; Wei Zhao; Jie Li
Journal:  Front Pharmacol       Date:  2020-05-13       Impact factor: 5.810

Review 4.  Anaplastic Thyroid Carcinoma: An Update.

Authors:  Arnaud Jannin; Alexandre Escande; Abir Al Ghuzlan; Pierre Blanchard; Dana Hartl; Benjamin Chevalier; Frédéric Deschamps; Livia Lamartina; Ludovic Lacroix; Corinne Dupuy; Eric Baudin; Christine Do Cao; Julien Hadoux
Journal:  Cancers (Basel)       Date:  2022-02-19       Impact factor: 6.639

5.  Differences Between Cancer-Specific Survival of Patients With Anaplastic and Primary Squamous Cell Thyroid Carcinoma and Factors Influencing Prognosis: A SEER Database Analysis.

Authors:  Shuai Jin; Xiangmei Liu; Dandan Peng; Dahuan Li; Yuan-Nong Ye
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-10       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.